Intercept Pharmaceuticals to Conduct One-on-One Meetings with Investors at the Citi 17th Annual BioPharma Conference September 8, 2022
Intercept Pharmaceuticals (Nasdaq: ICPT) will participate in investor meetings at the Citi 17th Annual BioPharma Conference on September 8, 2022, in Boston. This event focuses on the development of therapeutics for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis. Investors interested in meeting with the management team can contact Nareg Sagherian to check availability. For more details, visit www.interceptpharma.com.
- Participation in the prestigious Citi 17th Annual BioPharma Conference, enhancing visibility among investors.
- None.
MORRISTOWN, N.J., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that it will be participating in investor meetings at the Citi 17th Annual BioPharma Conference at the Four Seasons Hotel in Boston on September 8, 2022.
Meeting Details
For investors attending the conference who wish to meet with the Intercept management team, please reach out to Nareg Sagherian at Intercept to check the team’s availability.
About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
Contact
For more information about Intercept, please contact:
Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com
FAQ
When will Intercept Pharmaceuticals participate in the Citi 17th Annual BioPharma Conference?
What is the focus of Intercept Pharmaceuticals?
How can investors meet with Intercept Pharmaceuticals at the conference?
